Controversies in orthopaedic oncology
- PMID: 38689572
- DOI: 10.1302/0301-620X.106B5.BJJ-2023-1381
Controversies in orthopaedic oncology
Abstract
Chondrosarcoma is the second most common surgically treated primary bone sarcoma. Despite a large number of scientific papers in the literature, there is still significant controversy about diagnostics, treatment of the primary tumour, subtypes, and complications. Therefore, consensus on its day-to-day treatment decisions is needed. In January 2024, the Birmingham Orthopaedic Oncology Meeting (BOOM) attempted to gain global consensus from 300 delegates from over 50 countries. The meeting focused on these critical areas and aimed to generate consensus statements based on evidence amalgamation and expert opinion from diverse geographical regions. In parallel, periprosthetic joint infection (PJI) in oncological reconstructions poses unique challenges due to factors such as adjuvant treatments, large exposures, and the complexity of surgery. The meeting debated two-stage revisions, antibiotic prophylaxis, managing acute PJI in patients undergoing chemotherapy, and defining the best strategies for wound management and allograft reconstruction. The objectives of the meeting extended beyond resolving immediate controversies. It sought to foster global collaboration among specialists attending the meeting, and to encourage future research projects to address unsolved dilemmas. By highlighting areas of disagreement and promoting collaborative research endeavours, this initiative aims to enhance treatment standards and potentially improve outcomes for patients globally. This paper sets out some of the controversies and questions that were debated in the meeting.
© 2024 Jeys et al.
Conflict of interest statement
A. Puri is a member of the editorial board of The Bone & Joint Journal. P. Ruggieri reports consulting fees from Exactech and Stryker, unrelated to this study. M. T. Houdek reports consulting fees from Link Orthopedics, unrelated to this study. E. Botello reports consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, and support for attending meetings and/or travel from Zimmer Biomet, all of which are unrelated to this study. G. V. Morris reports consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, and support for attending meetings and/or travel from Implantcast, all of which are unrelated to this study.
References
-
- Enneking WF . History of orthopedic oncology in the United States: progress from the past, prospects for the future . Cancer Treat Res . 2009 ; 152 : 529 – 571 . 10.1007/978-1-4419-0284-9_32 20213414
-
- No authors listed . Bone sarcoma statistics . Cancer Research UK . 2023 . https://www.cancerresearchuk.org/health-professional/cancer-statistics/s... ( date last accessed 20 February 2024 ).
-
- Evaniew N , Nuttall J , Farrokhyar F , Bhandari M , Ghert M . What are the levels of evidence on which we base decisions for surgical management of lower extremity bone tumors? Clin Orthop Relat Res . 2014 ; 472 ( 1 ): 8 – 15 . 10.1007/s11999-013-3311-1 24081669
-
- Kantrowitz A . The science court experiment . Science . 1976 ; 194 ( 4260 ): 6 . 10.1126/science.194.4260.6-a 17793045
-
- Schneider PJ , Evaniew N , McKay P , Ghert M . Moving forward through consensus: a modified Delphi approach to determine the top research priorities in orthopaedic oncology . Clin Orthop Relat Res . 2017 ; 475 ( 12 ): 3044 – 3055 . 10.1007/s11999-017-5482-7 28856514
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical